There is a pressing need for tests that can accurately predict response to immunotherapies, writes Cliff Hoyt, our VP of Translational & Scientific Affairs, in a review article for Frontiers in Molecular Biosciences. Established methods are limited in the amount of information they can pull out of formalin- fixed, paraffin-embedded (FFPE) tissue sections. Conventional immunohistochemistry (IHC), for example, is constrained to one or two protein markers, which cannot capture the full breadth of cellular interactions in the tumor microenvironment.
Multispectral imaging of multiplex immunofluorescence (mIF) has emerged as a tool with significant predictive capabilities for immunotherapy response. Multispectral mIF enables deeper interrogation into the spatial biology of the tumor microenvironment, including the capture of spatially resolved, cell-to-cell interactions. There is growing evidence that spatial biology is key to understanding immunotherapy response and clinical outcomes, and thus it is critical to develop mIF assays that can be translated to the clinic.
Below, we outline some of the key points from Cliff’s article, including guiding principles for multispectral mIF and the requirements for translating this approach to clinical practice.